2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6243 Anxiety and depression following pediatric hematologic cancer diagnosis in the US: Short- and long-term incidence

Tara Beaulieu, PhD, MIPH, Xiaojian Chen2, Kerri Nottage3, Joanna Gendreau, DO4, Dina Gifkins, PhD, MPH5
1 Johnson & Johnson, Raritan, New Jersey, United States
2 Johnson & Johnson, Potomac, Maryland, United States
3 Johnson & Johnson, Raritan, New Jersey, United States
4 Johnson & Johnson, Horsham, Pennsylvania, United States
5 Johnson & Johnson, Raritan, New Jersey, United States

Background: The diagnosis and treatment of pediatric cancer can have deleterious effects on a child’s mental health. We evaluated incidence of anxiety and depressive disorders following a diagnosis of common pediatric cancers.  

Methods: Data from Optum’s de-identified Clinformatics® Data Mart Database were analyzed (2016-2025). For each cancer cohort, patients with >1 diagnosis code of leukemia [Leuk], and non-hodgkin lymphoma [NHL], ages 1-21 years were matched 1:1 to a general pediatric population. Each general cohort included patients ages 1-21 years without a cancer diagnosis, with healthcare encounters for a non-cancer condition and >1 health services utilization in the 365 days prior. Outcomes were defined for patients with >1 diagnosis code for each condition, with a wash-out period of 365 days prior to index date. Incidence proportions per 100 patients (IPs) and 95% confidence intervals (95% CIs) were calculated at 30-days, 180-days, 1-year, and 3-years post- diagnosis.

Results: For anxiety disorders, 734 matched patients remained in Leuk and 612 in NHL cohorts. For depressive disorders, matched cohorts included 750 for Leuk and 626 for NHL. Median ages for Leuk and NHL were 11-12 yrs, and 15-16yrs, respectively. IPs of anxiety were elevated among cancer patients vs. controls at 30-days (Leuk: 13 [10.8-16.3] vs. 0 [0-0.5]; NHL: 5 [3.3-7.0] vs. 0 [0.1-1.4]), 180-days (Leuk: 55 [49.8-60.7] vs. 4 [2.3-5.2]; NHL: 26 [22.6-30.9] vs. 4 [2.6-6.0]), 1-year (Leuk: 81 [74.2-87.3] vs. 18 [15.4-21.8]; NHL: 45 [39.6-50.4] vs. 12 [9.8-15.5]), and 3-years (Leuk: 132 [123.7-140.5] vs. 41 [36.8-46.2]; NHL: 109 [100.6-117.2] vs. 38 [33.6-43.6]). IPs of depressive disorders showed a similar trend, however, IPs in NHL patients were lower than controls at 1- and 3-years post-diagnosis. (30-days (Leuk: 1 [0.2-1.6] vs. 0 [0-0.5]; NHL: 1 [0.4-2.1] vs. 0 [0.1-1.4]), 180-days (Leuk: 5 [3.7-7.1] vs. 3 [2.3-5.1]; NHL: 6 [4.4-8.5] vs. 3 [2.1-5.1]), 1-year (Leuk: 9 [7.4-11.9] vs. 8 [6.5-10.7]; NHL: 9 [7.0-12.0] vs. 12 [9.4-15.0]), and 3-years (Leuk: 23 [19.3-26.2] vs. 20 [17.3-23.9]; NHL: 22 [18.5-26.0] vs. 31 [26.6-35.5]).

Conclusion: In both cohorts involving US pediatric cancer patients, the incidence of anxiety disorders was consistently elevated, especially at 3-years post-diagnosis. At each evaluated time point, the incidence of anxiety disorders was numerically higher among leukemia patients compared with NHL patients. Furthermore, across both cancer cohorts, the incidence of anxiety disorders consistently exceeded that of depressive disorders. In NHL patients, the incidence of depressive disorders was lower as compared with controls at 1-and 3-year post-diagnosis, which may be explained by the shorter duration of therapy (6-8 months) or the overall favorable prognosis. Vigilance among clinicians for early detection and treatment of mental health conditions in pediatric cancer patients is warranted.

Tara Beaulieu, PhD, MIPH: Johnson & Johnson - Current equity holder in publicly-traded company; Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment